Article
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Apr 2023
Elkrief Arielle, Makhnin Alex, Moses Khadeja A, Ahn Linda S, Preeshagul Isabel R, Iqbal Afsheen N, Hayes Sara A, Plodkowski Andrew J, Paik Paul K, Ladanyi Marc, Kris Mark G, Riely Gregory J, Michor Franziska, Yu Helena A
Abstract excerpt
PURPOSE: Primary and acquired resistance to osimertinib remain significant challenges for patients with EGFR-mutant lung cancers. Acquired EGFR alterations such as EGFR T790M or C797S mediate resistance to EGFR tyrosine kinase inhibitors (TKI) and combination therapy with dual EGFR TKIs may prevent or reverse on-target resistance. PATIENTS AND METHODS: We conducted two prospective, phase I/II trials assessing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.